A study of a radioactive drug for men with metastatic prostate cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new radioactive drug (called [177Lu]Ludotadipep) that targets a molecule on prostate cancer cells. It may help slow cancer growth in men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 19 or older.
- Your prostate cancer has spread and is no longer controlled by hormone therapy (called castration-resistant).
- You have had at least one newer hormone therapy (like enzalutamide or abiraterone).
- You have had at least one, but no more than two, chemotherapy treatments (like docetaxel) — or you may not have had docetaxel if your doctor says you can’t or won’t take it.
- A special scan (PSMA PET/CT) shows your cancer is PSMA-positive (meaning the cancer cells take up the tracer).
- You have not had prior PSMA-targeted therapy (like lutetium-177 or other radioligand treatments).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests a new radioactive treatment, called 177Lu-NYM032, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It aims to see if this treatment can slow the cancer's growth and improve outcomes.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.